Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A Single Dose PK Study of OxyNorm® immediate-release capsules 5, 10, and 20mg, and a multiple-dose PK Study of OxyNorm® immediate-release capsules 10mg in Chinese patients with pain.It will be a single center, open label, randomized, oral administration study.
Single dose: The subjects will be randomized to receive a single dose of OxyNorm® immediate-release capsules 5, 10, and 20mg.
Multiple dose: The subjects will take 3 days OxyNorm® capsule 10mg, once every 6 hours, 10mg per dose. In the morning of the 4th day, the subjects will take single dose of OxyNorm® capsule 10mg. On the 5th day, all the subjects complete the study.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Oxycodone Hydrochloride 5 mg Capsules | Experimental | Group 1: single dose Oxycodone Hydrochloride 5 mg Capsules after 10 hours fasting |
|
| Oxycodone Hydrochloride 10 mg Capsules | Experimental | Group 2: single dose Oxycodone Hydrochloride 10 mg Capsules after 10 hours fasting |
|
| Oxycodone Hydrochloride 20 mg Capsules | Experimental | Group 3: single dose Oxycodone Hydrochloride 20 mg Capsules after 10 hours fasting |
|
| Oxycodone Hydrochloride 10 mg Capsules(multi-dose) | Experimental | Group 4: multi-dose 4 times per day Oxycodone Hydrochloride 10mg Capsules for 3 days, and one dose on 4th day morning |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Oxycodone hydrochloride | Drug | The subjects will be randomized to receive either a single dose of OxyNorm® Capsules 5, 10, 20mg, or multiple-dose OxyNorm® Capsules 10 mg for 13 times. |
| Measure | Description | Time Frame |
|---|---|---|
| AUC0-t and AUC0-∞ for Participants Who Received a Single Dose | To calculate AUC0-t AUC0-∞of Oxycondone,Noroxycodone,Hydroxymorphine, Normethoxymorphone with Non-atrioventricular model method.Plasma concentrations of Oxycodone Hydrochloride single dose 5mg,10mg,20mg will be analyzed. | blood sample at predose,15min,30min,45min,1,1.5,2,3,4,6,8,12,24hr post-dose. |
| Cmax,Clast for Participants Who Received a Single Dose | To calculate Cmax,Clast of Oxycondone,Noroxycodone,Hydroxymorphine, Normethoxymorphone with Non-atrioventricular model method in single dose 5mg,10mg,20mg. | blood sample at predose,15min,30min,45min,1,1.5,2,3,4,6,8,12,24hr post-dose. |
| Tmax,t1/2 for Participants Who Received a Single Dose | To calculate Tmax,t1/2 of Oxycondone,Noroxycodone,Hydroxymorphine, Normethoxymorphone with Non-atrioventricular model method in single dose 5mg,10mg,20mg. | blood sample at predose,15min,30min,45min,1,1.5,2,3,4,6,8,12,24hr post-dose. |
| Clearance Rate for Participants Who Received a Single Dose | To calculate CL of Oxycondone,Noroxycodone,Hydroxymorphine, Normethoxymorphone with Non-atrioventricular model method in single dose 5mg,10mg,20mg. | blood sample at predose,15min,30min,45min,1,1.5,2,3,4,6,8,12,24hr post-dose. |
| Vd for Participants Who Received a Single Dose | To calculate Apparent Distribution Volume (Vd) Vd of Oxycondone,Noroxycodone,Hydroxymorphine, Normethoxymorphone with Non-atrioventricular model method in single dose 5mg,10mg,20mg. | blood sample at predose,15min,30min,45min,1,1.5,2,3,4,6,8,12,24hr post-dose. |
| ke for Participants Who Received a Single Dose |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Mundipharma China Ltd. | Mundipharma China Ltd. | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Affiliated Hospital to Academy of Military Medical Science of China People's Liberation Army | Beijing | China |
The study has a 7-days screening phase, for the subject who meet all the inclusion and exclusion criteria was dosed without run-in or wash out period.
The study was conducted in phase I unit in two public hospitals, the first subject took the first dose study medication on 13May2011, the last subject took the last dose on 6Jul2012.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Oxycodone Hydrochloride Single Dose(5mg) | Group 1: single dose Oxycodone Hydrochloride 5 mg Capsules after 10 hours fasting |
| FG001 | Oxycodone Hydrochloride Single Dose(10mg) | Group 2: single dose Oxycodone Hydrochloride 10 mg Capsules after 10 hours fasting |
| FG002 | Oxycodone Hydrochloride Single Dose(20mg) | Group 3: single dose Oxycodone Hydrochloride 20 mg Capsules after 10 hours fasting |
| FG003 | Oxycodone Hydrochloride Multiple Dose | Group 4: multi-dose 4 times per day Oxycodone Hydrochloride 10mg Capsules for 3 days, and one dose on 4th day morning |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
PP Population
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Oxycodone Hydrochloride Single Dose(5mg) | Group 1: single dose Oxycodone Hydrochloride 5 mg Capsules after 10 hours fasting |
| BG001 | Oxycodone Hydrochloride Single Dose(10mg) | Group 2: single dose Oxycodone Hydrochloride 10 mg Capsules after 10 hours fasting |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | PP population |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | AUC0-t and AUC0-∞ for Participants Who Received a Single Dose | To calculate AUC0-t AUC0-∞of Oxycondone,Noroxycodone,Hydroxymorphine, Normethoxymorphone with Non-atrioventricular model method.Plasma concentrations of Oxycodone Hydrochloride single dose 5mg,10mg,20mg will be analyzed. | PP Population | Posted | Mean | Standard Deviation | ng*hr*ml | blood sample at predose,15min,30min,45min,1,1.5,2,3,4,6,8,12,24hr post-dose. |
|
Single dose group the screening period is maximal 7 days, then 1 day dosing and sampling following by 1 day safety follow up, so total 9 days maximal. Multiple dose group the screening period is maximal 7 days, then 4 days dosing and sampleing following by 1 day safety follow up, so total 12 days maximal.
No difference with the clinicaltrials.gov definition
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Oxycodone Hydrochloride Single Dose(5mg) | Group 1: single dose Oxycodone Hydrochloride 5 mg Capsules after 10 hours fasting |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Dizziness | Nervous system disorders | Non-systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Ms. Dan Zhu, Clinical operation and quality lead of the study | Mundipharma (China) Pharmaceutical Co.Ltd | +8610 6563 6891 | dan.zhu@mundipharma.com.cn |
Not provided
| ID | Term |
|---|---|
| D010146 | Pain |
| ID | Term |
|---|---|
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| D010098 | Oxycodone |
| ID | Term |
|---|---|
| D003061 | Codeine |
| D009022 | Morphine Derivatives |
| D009019 | Morphinans |
| D053610 | Opiate Alkaloids |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
To calculate Terminal Elimination Rate (ke) of Oxycondone,Noroxycodone,Hydroxymorphine, Normethoxymorphone with Non-atrioventricular model method in single dose 5mg,10mg,20mg. |
| blood sample at predose,15min,30min,45min,1,1.5,2,3,4,6,8,12,24hr post-dose. |
| AUCss for Participants Who Received Multiple Dose | To calculate AUCss of Oxycondone,Noroxycodone,Hydroxymorphine, Normethoxymorphone with Non-atrioventricular model method in multiple dose 10mg. | Predose for the 1st, 2nd, 3rd day and predose,15min,30min,45min,1,1.5,2,3,4,6,8,12,24 post dose on the 4th day. |
| Css_min,Css_max and Css_av for Participants Who Received Multiple Dose | To calculate Css_min,Css_max and Css_av of Oxycondone,Noroxycodone,Hydroxymorphine, Normethoxymorphone with Non-atrioventricular model method in multiple dose 10mg. | Predose for the 1st, 2nd, 3rd day and predose,15min,30min,45min,1,1.5,2,3,4,6,8,12,24 post dose on the 4th day. |
| Tmax,t1/2 for Participants Who Received Multiple Dose | To calculate Tmax,t1/2 of Oxycondone,Noroxycodone,Hydroxymorphine, Normethoxymorphone with Non-atrioventricular model method in multiple dose 10mg. | Predose for the 1st, 2nd, 3rd day and predose,15min,30min,45min,1,1.5,2,3,4,6,8,12,24 post dose on the 4th day. |
| CL for Participants Who Received Multiple Dose | To calculate Clearance rate (CL) of Oxycondone,Noroxycodone,Hydroxymorphine, Normethoxymorphone with Non-atrioventricular model method in multiple dose 10mg. | Predose for the 1st, 2nd, 3rd day and predose,15min,30min,45min,1,1.5,2,3,4,6,8,12,24 post dose on the 4th day. |
| Fluctuation Index (DF) for Participants Who Received Multiple Dose | To calculate Fluctuation index (DF) of Drug Valley and Peak Concentration of Oxycondone,Noroxycodone,Hydroxymorphine, Normethoxymorphone with Non-atrioventricular model method in multiple dose 10mg. | Predose for the 1st, 2nd, 3rd day and predose,15min,30min,45min,1,1.5,2,3,4,6,8,12,24 post dose on the 4th day. |
| The Excretion of Oxycondone, Noroxycodone, Hydroxymorphine,Normethoxymorphone in Urine(Single Dose) | The excretion of drugs were calculated according to the concentration and volume of drugs in urine after single dose. | Pre-dose,post dose0-2h,post dose2-4h,post dose4-8h,post dose8-12h,post dose12-24h |
| Cumulative Excretion of Oxycondone, Noroxycodone, Hydroxymorphine,Normethoxymorphone in Urine(Single Dose) | Cumulative excretion of drugs were calculated according to the concentration and volume of drugs in urine after single dose. | post dose0-2h,post dose2-4h,post dose4-8h,post dose8-12h,post dose12-24h |
| Average Cumulative Excretion Rate of Oxycondone, Noroxycodone, Hydroxymorphine,Normethoxymorphone in Urine(Single Dose) | Average cumulative excretion rate of drugs were calculated according to the concentration and volume of drugs in urine after single dose. | post dose 24h |
| The Excretion of Oxycondone, Noroxycodone, Hydroxymorphine,Normethoxymorphone in Urine(Multiple Dose) | The excretion of drugs were calculated according to the concentration and volume of drugs in urine after multiple dose on the 4th day. | Pre-dose,post dose0-2h,post dose2-4h,post dose4-8h,post dose8-12h,post dose12-24h on the 4th day |
| Cumulative Excretion of Oxycondone, Noroxycodone, Hydroxymorphine,Normethoxymorphone in Urine(Mutilple Dose) | Cumulative excretion of drugs were calculated according to the concentration and volume of drugs in urine after multiple dose on the 4th day . | post dose0-2h,post dose2-4h,post dose4-8h,post dose8-12h,post dose12-24h on the 4th day |
| Adverse Event |
|
| BG002 | Oxycodone Hydrochloride Single Dose(20mg) | Group 3: single dose Oxycodone Hydrochloride 20 mg Capsules after 10 hours fasting |
| BG003 | Oxycodone Hydrochloride Multiple Dose(10mg) | Group 4: multi-dose 4 times per day Oxycodone Hydrochloride 10mg Capsules for 3 days, and one dose on 4th day morning |
| BG004 | Total | Total of all reporting groups |
| Standard Deviation |
| year |
|
| Sex: Female, Male | PP Population | Count of Participants | Participants |
|
| Race (NIH/OMB) | PP Population | Count of Participants | Participants |
|
| Region of Enrollment | PP Population | Number | participants |
|
| OG002 | Oxycodone Hydrochloride Single Dose 20 mg | Group 3: single dose Oxycodone Hydrochloride 20 mg Capsules after 10 hours fasting |
|
|
| Primary | Cmax,Clast for Participants Who Received a Single Dose | To calculate Cmax,Clast of Oxycondone,Noroxycodone,Hydroxymorphine, Normethoxymorphone with Non-atrioventricular model method in single dose 5mg,10mg,20mg. | PP population | Posted | Mean | Standard Deviation | ng*mL | blood sample at predose,15min,30min,45min,1,1.5,2,3,4,6,8,12,24hr post-dose. |
|
|
|
| Primary | Tmax,t1/2 for Participants Who Received a Single Dose | To calculate Tmax,t1/2 of Oxycondone,Noroxycodone,Hydroxymorphine, Normethoxymorphone with Non-atrioventricular model method in single dose 5mg,10mg,20mg. | PP popluation | Posted | Mean | Standard Deviation | hour | blood sample at predose,15min,30min,45min,1,1.5,2,3,4,6,8,12,24hr post-dose. |
|
|
|
| Primary | Clearance Rate for Participants Who Received a Single Dose | To calculate CL of Oxycondone,Noroxycodone,Hydroxymorphine, Normethoxymorphone with Non-atrioventricular model method in single dose 5mg,10mg,20mg. | PP popuplation | Posted | Mean | Standard Deviation | L*hour | blood sample at predose,15min,30min,45min,1,1.5,2,3,4,6,8,12,24hr post-dose. |
|
|
|
| Primary | Vd for Participants Who Received a Single Dose | To calculate Apparent Distribution Volume (Vd) Vd of Oxycondone,Noroxycodone,Hydroxymorphine, Normethoxymorphone with Non-atrioventricular model method in single dose 5mg,10mg,20mg. | PP population | Posted | Mean | Standard Deviation | L | blood sample at predose,15min,30min,45min,1,1.5,2,3,4,6,8,12,24hr post-dose. |
|
|
|
| Primary | ke for Participants Who Received a Single Dose | To calculate Terminal Elimination Rate (ke) of Oxycondone,Noroxycodone,Hydroxymorphine, Normethoxymorphone with Non-atrioventricular model method in single dose 5mg,10mg,20mg. | PP population | Posted | Mean | Standard Deviation | h^-1 | blood sample at predose,15min,30min,45min,1,1.5,2,3,4,6,8,12,24hr post-dose. |
|
|
|
| Primary | AUCss for Participants Who Received Multiple Dose | To calculate AUCss of Oxycondone,Noroxycodone,Hydroxymorphine, Normethoxymorphone with Non-atrioventricular model method in multiple dose 10mg. | PP population | Posted | Mean | Standard Deviation | ng*hours*mL | Predose for the 1st, 2nd, 3rd day and predose,15min,30min,45min,1,1.5,2,3,4,6,8,12,24 post dose on the 4th day. |
|
|
|
| Primary | Css_min,Css_max and Css_av for Participants Who Received Multiple Dose | To calculate Css_min,Css_max and Css_av of Oxycondone,Noroxycodone,Hydroxymorphine, Normethoxymorphone with Non-atrioventricular model method in multiple dose 10mg. | multiple dose group has 14 subjects | Posted | Mean | Standard Deviation | ng/ml | Predose for the 1st, 2nd, 3rd day and predose,15min,30min,45min,1,1.5,2,3,4,6,8,12,24 post dose on the 4th day. |
|
|
|
| Primary | Tmax,t1/2 for Participants Who Received Multiple Dose | To calculate Tmax,t1/2 of Oxycondone,Noroxycodone,Hydroxymorphine, Normethoxymorphone with Non-atrioventricular model method in multiple dose 10mg. | multiple dose group has 14 subjects | Posted | Mean | Standard Deviation | hour | Predose for the 1st, 2nd, 3rd day and predose,15min,30min,45min,1,1.5,2,3,4,6,8,12,24 post dose on the 4th day. |
|
|
|
| Primary | CL for Participants Who Received Multiple Dose | To calculate Clearance rate (CL) of Oxycondone,Noroxycodone,Hydroxymorphine, Normethoxymorphone with Non-atrioventricular model method in multiple dose 10mg. | multiple dose group has 14 subjects | Posted | Mean | Standard Deviation | L*hour | Predose for the 1st, 2nd, 3rd day and predose,15min,30min,45min,1,1.5,2,3,4,6,8,12,24 post dose on the 4th day. |
|
|
|
| Primary | Fluctuation Index (DF) for Participants Who Received Multiple Dose | To calculate Fluctuation index (DF) of Drug Valley and Peak Concentration of Oxycondone,Noroxycodone,Hydroxymorphine, Normethoxymorphone with Non-atrioventricular model method in multiple dose 10mg. | multiple dose group has 14 subjects | Posted | Mean | Standard Deviation | ng/ml | Predose for the 1st, 2nd, 3rd day and predose,15min,30min,45min,1,1.5,2,3,4,6,8,12,24 post dose on the 4th day. |
|
|
|
| Primary | The Excretion of Oxycondone, Noroxycodone, Hydroxymorphine,Normethoxymorphone in Urine(Single Dose) | The excretion of drugs were calculated according to the concentration and volume of drugs in urine after single dose. | Posted | Mean | Standard Deviation | μg | Pre-dose,post dose0-2h,post dose2-4h,post dose4-8h,post dose8-12h,post dose12-24h |
|
|
|
| Primary | Cumulative Excretion of Oxycondone, Noroxycodone, Hydroxymorphine,Normethoxymorphone in Urine(Single Dose) | Cumulative excretion of drugs were calculated according to the concentration and volume of drugs in urine after single dose. | Posted | Mean | Standard Deviation | μg | post dose0-2h,post dose2-4h,post dose4-8h,post dose8-12h,post dose12-24h |
|
|
|
| Primary | Average Cumulative Excretion Rate of Oxycondone, Noroxycodone, Hydroxymorphine,Normethoxymorphone in Urine(Single Dose) | Average cumulative excretion rate of drugs were calculated according to the concentration and volume of drugs in urine after single dose. | Posted | Mean | Standard Deviation | % of ug | post dose 24h |
|
|
|
| Primary | The Excretion of Oxycondone, Noroxycodone, Hydroxymorphine,Normethoxymorphone in Urine(Multiple Dose) | The excretion of drugs were calculated according to the concentration and volume of drugs in urine after multiple dose on the 4th day. | Posted | Mean | Standard Deviation | μg | Pre-dose,post dose0-2h,post dose2-4h,post dose4-8h,post dose8-12h,post dose12-24h on the 4th day |
|
|
|
| Primary | Cumulative Excretion of Oxycondone, Noroxycodone, Hydroxymorphine,Normethoxymorphone in Urine(Mutilple Dose) | Cumulative excretion of drugs were calculated according to the concentration and volume of drugs in urine after multiple dose on the 4th day . | Posted | Mean | Standard Deviation | μg | post dose0-2h,post dose2-4h,post dose4-8h,post dose8-12h,post dose12-24h on the 4th day |
|
|
|
| 0 |
| 15 |
| 0 |
| 15 |
| 8 |
| 15 |
| EG001 | Oxycodone Hydrochloride Single Dose(10mg) | Group 2: single dose Oxycodone Hydrochloride 10 mg Capsules after 10 hours fasting | 0 | 15 | 0 | 15 | 11 | 15 |
| EG002 | Oxycodone Hydrochloride Single Dose(20mg) | Group 3: single dose Oxycodone Hydrochloride 20 mg Capsules after 10 hours fasting | 0 | 15 | 0 | 15 | 14 | 15 |
| EG003 | Oxycodone Hydrochloride Multiple Dose(10mg) | Group 4: multi-dose 4 times per day Oxycodone Hydrochloride 10mg Capsules for 3 days, and one dose on 4th day morning | 0 | 16 | 0 | 16 | 12 | 16 |
| Nausea | Gastrointestinal disorders | Non-systematic Assessment |
|
| Drowsiness | Nervous system disorders | Non-systematic Assessment |
|
| Vomiting | Gastrointestinal disorders | Non-systematic Assessment |
|
Not provided
| D000470 |
| Alkaloids |
| D006571 | Heterocyclic Compounds |
| D006572 | Heterocyclic Compounds, Bridged-Ring |
| D006576 | Heterocyclic Compounds, 4 or More Rings |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D010616 | Phenanthrenes |
| D011084 | Polycyclic Aromatic Hydrocarbons |
| D011083 | Polycyclic Compounds |
| Male |
|
| Asian |
|
| Native Hawaiian or Other Pacific Islander |
|
| Black or African American |
|
| White |
|
| More than one race |
|
| Unknown or Not Reported |
|
| Noroxycodone(Cmax) |
|
|
| Hydroxymorphine(Cmax) |
|
|
| Normethoxymorphone(Cmax) |
|
|
| Oxycodone(Clast) |
|
|
| Noroxycodone(Clast) |
|
|
| Hydroxymorphine(Clast) |
|
|
| Normethoxymorphone(Clast) |
|
|
| Oxycodone (t1/2) |
|
|
| Noroxycodone (Tmax) |
|
|
| Noroxycodone (t1/2) |
|
|
| Hydroxymorphine(Tmax) |
|
|
| Hydroxymorphine (t1/2) |
|
|
| Normethoxymorphone(Tmax) |
|
|
| Normethoxymorphone(t1/2) |
|
|
| Noroxycodone (CL) |
|
|
| Hydroxymorphine(CL) |
|
|
| Normethoxymorphone(CL) |
|
|
| Noroxycodone |
|
|
| Hydroxymorphine |
|
|
| Normethoxymorphone |
|
|
| Noroxycodone |
|
|
| Hydroxymorphine |
|
|
| Normethoxymorphone |
|
|
|
| Hydroxymorphine |
|
|
| Normethoxymorphone |
|
|
|
| Hydroxymorphine(Css_min) |
|
|
| Normethoxymorphone(Css_min) |
|
|
| Oxycodone(Css_max ) |
|
|
| Noroxycodone(Css_max ) |
|
|
| Hydroxymorphine(Css_max ) |
|
|
| Normethoxymorphone(Css_max ) |
|
|
| Oxycodone(Css_av) |
|
|
| Noroxycodone(Css_av) |
|
|
| Hydroxymorphine(Css_av) |
|
|
| Normethoxymorphone(Css_av) |
|
|
| Title | Measurements |
|---|---|
|
| Normethoxymorphone( Tmax) |
|
| Oxycodone(t1/2) |
|
| Noroxycodone(t1/2) |
|
| Hydroxymorphine(t1/2) |
|
| Normethoxymorphone(t1/2) |
|
|
| Hydroxymorphine |
|
|
| Normethoxymorphone |
|
|
|
| Hydroxymorphine |
|
|
| Normethoxymorphone |
|
|
|
| Oxycondone(post dose2-4h) |
|
| Oxycondone(post dose4-8h) |
|
| Oxycondone(post dose8-12h) |
|
| Oxycondone(post dose12-24h) |
|
| Noroxycodone(Pre-dose) |
|
| Noroxycodone(post dose0-2h) |
|
| Noroxycodone(post dose2-4h) |
|
| Noroxycodone(post dose4-8h) |
|
| Noroxycodone(post dose8-12h) |
|
| Noroxycodone(post dose12-24h) |
|
| Hydroxymorphine(Pre-dose) |
|
| Hydroxymorphine(post dose0-2h) |
|
| Hydroxymorphine(post dose2-4h) |
|
| Hydroxymorphine(post dose4-8h) |
|
| Hydroxymorphine(post dose8-12h) |
|
| Hydroxymorphine(post dose12-24h) |
|
| Normethoxymorphone(Pre-dose) |
|
| Normethoxymorphone(post dose0-2h) |
|
| Normethoxymorphone(post dose2-4h) |
|
| Normethoxymorphone(post dose4-8h) |
|
| Normethoxymorphone(post dose8-12h) |
|
| Normethoxymorphone(post dose12-24h) |
|
|
| Oxycondone(post dose4-8h) |
|
| Oxycondone(post dose8-12h) |
|
| Oxycondone(post dose12-24h) |
|
| Noroxycodone(post dose0-2h) |
|
| Noroxycodone(post dose2-4h) |
|
| Noroxycodone(post dose4-8h) |
|
| Noroxycodone(post dose8-12h) |
|
| Noroxycodone(post dose12-24h) |
|
| Hydroxymorphine(post dose0-2h) |
|
| Hydroxymorphine(post dose2-4h) |
|
| Hydroxymorphine(post dose4-8h) |
|
| Hydroxymorphine(post dose8-12h) |
|
| Hydroxymorphine(post dose12-24h) |
|
| Normethoxymorphone(post dose0-2h) |
|
| Normethoxymorphone(post dose2-4h) |
|
| Normethoxymorphone(post dose4-8h) |
|
| Normethoxymorphone(post dose8-12h) |
|
| Normethoxymorphone(post dose12-24h) |
|
|
| Hydroxymorphine |
|
| Normethoxymorphone |
|
| Title | Measurements |
|---|---|
|
| Oxycondone(post dose4-8h) |
|
| Oxycondone(post dose8-12h) |
|
| Oxycondone(post dose12-24h) |
|
| Noroxycodone(Pre-dose) |
|
| Noroxycodone(post dose0-2h) |
|
| Noroxycodone(post dose2-4h) |
|
| Noroxycodone(post dose4-8h) |
|
| Noroxycodone(post dose8-12h) |
|
| Noroxycodone(post dose12-24h) |
|
| Hydroxymorphine(Pre-dose) |
|
| Hydroxymorphine(post dose0-2h) |
|
| Hydroxymorphine(post dose2-4h) |
|
| Hydroxymorphine(post dose4-8h) |
|
| Hydroxymorphine(post dose8-12h) |
|
| Hydroxymorphine(post dose12-24h) |
|
| Normethoxymorphone(Pre-dose) |
|
| Normethoxymorphone(post dose0-2h) |
|
| Normethoxymorphone(post dose2-4h) |
|
| Normethoxymorphone(post dose4-8h) |
|
| Normethoxymorphone(post dose8-12h) |
|
| Normethoxymorphone(post dose12-24h) |
|
| Title | Measurements |
|---|---|
|
| Oxycondone(post dose8-12h) |
|
| Oxycondone(post dose12-24h) |
|
| Noroxycodone(post dose0-2h) |
|
| Noroxycodone(post dose2-4h) |
|
| Noroxycodone(post dose4-8h) |
|
| Noroxycodone(post dose8-12h) |
|
| Noroxycodone(post dose12-24h) |
|
| Hydroxymorphine(post dose0-2h) |
|
| Hydroxymorphine(post dose2-4h) |
|
| Hydroxymorphine(post dose4-8h) |
|
| Hydroxymorphine(post dose8-12h) |
|
| Hydroxymorphine(post dose12-24h) |
|
| Normethoxymorphone(post dose0-2h) |
|
| Normethoxymorphone(post dose2-4h) |
|
| Normethoxymorphone(post dose4-8h) |
|
| Normethoxymorphone(post dose8-12h) |
|
| Normethoxymorphone(post dose12-24h) |
|